In non-small cell lung cancer (NSCLC), genetic biomarkers have been shown to predict the efficacy of targeted therapies, especially those targeting specific tyrosine kinase receptors and immune checkpoint inhibitors (9). Here, NTRK1 is linked to non-small cell lung carcinoma.